Joshua A Barocas1, Lisa Baker2, Shawnika J Hull3, Scott Stokes4, Ryan P Westergaard5. 1. Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, GrJ-504, Boston, MA, 02114, USA; Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, UWMFCB 5th floor, Madison, WI 53705, USA. Electronic address: jbarocas@partners.org. 2. Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, UWMFCB 5th floor, Madison, WI 53705, USA. Electronic address: lmbaker@medicine.wisc.edu. 3. University of Wisconsin, School of Journalism Mass Communication, 821 University Ave, 5164 Vilas Hall 53705, USA. Electronic address: sjhull@wisc.edu. 4. AIDS Resource Center of Wisconsin, 3716W. Wisconsin Ave, Milwaukee, WI 53208, USA. Electronic address: Scott.Stokes@arcw.org. 5. Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, UWMFCB 5th floor, Madison, WI 53705, USA; Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, 707 WARF Building, 610 North Walnut St, Madison WI 53726, USA. Electronic address: rpw@medicine.wisc.edu.
Abstract
BACKGROUND: Incarceration is common among people who inject drugs. Prior research has shown that incarceration is a marker of elevated risk for opioid overdose, suggesting that the criminal justice system may be an important, under-utilized venue for implementing overdose prevention strategies. To better understand the feasibility and acceptability of such strategies, we evaluated the utilization of naloxone-based overdose prevention training among people who inject drugs with and without a history of incarceration. METHODS: We surveyed clients who utilize a multi-site syringe exchange program (SEP) in 2 cities in the Midwestern United States. Participants completed an 88-item, computerized survey assessing history of incarceration, consequences associated with injection, injecting practices, and uptake of harm reduction strategies. RESULTS: Among 543 respondents who injected drugs in the prior 30 days, 243 (43%) reported prior incarceration. Comparing those with and without a history of incarceration, there were no significant differences with respect to age, gender, or race. Those who observed an overdose, experienced overdose, and received training to administer or have administered naloxone were more likely to report incarceration. Overall, 69% of previously incarcerated clients had been trained to administer naloxone. CONCLUSION: People who inject drugs with a history of incarceration appear to have a higher risk of opioid overdose than those never incarcerated, and are more willing to utilize naloxone as an overdose prevention strategy. Naloxone training and distribution is an important component of comprehensive prevention services for persons with opioid use disorders. Expansion of services for persons leaving correctional facilities should be considered.
BACKGROUND: Incarceration is common among people who inject drugs. Prior research has shown that incarceration is a marker of elevated risk for opioid overdose, suggesting that the criminal justice system may be an important, under-utilized venue for implementing overdose prevention strategies. To better understand the feasibility and acceptability of such strategies, we evaluated the utilization of naloxone-based overdose prevention training among people who inject drugs with and without a history of incarceration. METHODS: We surveyed clients who utilize a multi-site syringe exchange program (SEP) in 2 cities in the Midwestern United States. Participants completed an 88-item, computerized survey assessing history of incarceration, consequences associated with injection, injecting practices, and uptake of harm reduction strategies. RESULTS: Among 543 respondents who injected drugs in the prior 30 days, 243 (43%) reported prior incarceration. Comparing those with and without a history of incarceration, there were no significant differences with respect to age, gender, or race. Those who observed an overdose, experienced overdose, and received training to administer or have administered naloxone were more likely to report incarceration. Overall, 69% of previously incarcerated clients had been trained to administer naloxone. CONCLUSION:People who inject drugs with a history of incarceration appear to have a higher risk of opioid overdose than those never incarcerated, and are more willing to utilize naloxone as an overdose prevention strategy. Naloxone training and distribution is an important component of comprehensive prevention services for persons with opioid use disorders. Expansion of services for persons leaving correctional facilities should be considered.
Authors: Josiah D Rich; Amy E Boutwell; David C Shield; R Garrett Key; Michelle McKenzie; Jennifer G Clarke; Peter D Friedmann Journal: J Urban Health Date: 2005-05-25 Impact factor: 3.671
Authors: Ingrid A Binswanger; Marc F Stern; Richard A Deyo; Patrick J Heagerty; Allen Cheadle; Joann G Elmore; Thomas D Koepsell Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Karen H Seal; Robert Thawley; Lauren Gee; Joshua Bamberger; Alex H Kral; Dan Ciccarone; Moher Downing; Brian R Edlin Journal: J Urban Health Date: 2005-05-04 Impact factor: 3.671
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Seonaid Nolan; Jane Buxton; Sabina Dobrer; Huiru Dong; Kanna Hayashi; M J Milloy; Thomas Kerr; Julio Montaner; Evan Wood Journal: Public Health Rep Date: 2017-07-27 Impact factor: 2.792
Authors: Juliet M Flam-Ross; Josh Lown; Prasad Patil; Laura F White; Jianing Wang; Ashley Perry; Dennis Bailer; Michelle McKenzie; Anthony Thigpen; Roxxanne Newman; Meko Lincoln; Tyrone Mckinney; Dana Bernson; Joshua A Barocas Journal: Int J Drug Policy Date: 2021-12-09
Authors: Tyler S Bartholomew; Hansel E Tookes; Corinne Bullock; Jason Onugha; David W Forrest; Daniel J Feaster Journal: Int J Drug Policy Date: 2020-03-05
Authors: Christine E Grella; Erika Ostlie; Christy K Scott; Michael L Dennis; John Carnevale; Dennis P Watson Journal: Subst Abuse Treat Prev Policy Date: 2021-02-22